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ABSTRACT
The in-vitro susceptibility of an organism and the pharmacokinetics of an antimicrobial agent are two
basic factors on which the choice of standardised treatment regimens is based. However, the inter-
individual variability of these factors, which modifies the exposure of bacteria to an antibiotic in terms of
time and quantity, is not usually taken into account. In 87 patients treated with b-lactams (ceftriaxone,
cefepime or piperacillin), the probability of failure was greater when the infectious process was located
in tissues with barriers to the distribution of b-lactams. Mean MICs of piperacillin and cefepime, but not
ceftriaxone, were below the breakpoints in cases of both recovery and failure, but organisms isolated
from patients with a poor outcome had higher MICs. Therefore, the use of breakpoints to determine the
susceptibility of microorganisms was not satisfactory in predicting the outcome for a large number of
patients. If MICs are determined and plasma concentrations are monitored, dosages can be adjusted
according to these parameters, thereby allowing antibiotic treatment to be individualised.
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INTRODUCTION
In-vitro susceptibility assays often serve as the
basis for the choice of antimicrobial therapy,
although the correlation between in-vitro and in-
vivo results is generally not perfect [1,2]. Once the
sensitivity of an infecting organism has been
determined, the distribution characteristics of the
active antibiotics are evaluated with reference to
the location of the infection, and the most suitable
antibiotic is chosen after assessment of the
patient’s clinical condition. The dosage should
be decided on the basis of the pharmacokinetics of
the antimicrobial agent, as an adequate concen-
tration of the drug must be delivered to the site of
infection for antimicrobial therapy to be effective.
In most cases, the goal is to obtain plasma and ⁄ or
tissue concentrations that should at least equal the
MIC for the infecting organism.
Antimicrobial dosages were designed origin-
ally to maintain plasma concentrations above the
bacterial MIC throughout the dosing interval.
Other factors to be considered now include the
post-antibiotic effect and the acquisition of resist-
ance [3,4]. Nevertheless, the achievement of
therapeutic concentrations of an antimicrobial
agent at the site of infection and knowledge of
the susceptibility of the infecting organism
may not be sufficient to guarantee a cure. Indeed,
mortality percentages of 6–33% have been
reported for patients in whom the infecting
bacteria were susceptible to the treatment admin-
istered [3], with rates of clinical or microbiological
response of 54–100% [5].
In order to optimise antimicrobial use, certain
surrogatemarkers that define specific relationships
between the pharmacokinetic (PK) and pharmac-
odynamic (PD) characteristics of antimicrobials
have been used, with very good results, to predict
positive patient outcomes [6]. These pharmacoki-
netic–pharmacodynamic (PK ⁄PD) relationships
have become available as tools for individuali-
sing antimicrobial therapy, and have led to the
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optimisation of dosage regimens to improve the
outcome and reduce the selection of resistant
mutants. Standardised regimens of b-lactam anti-
biotics are currently used in the treatment of
infectious diseases, despite the fact that it has been
established thatmanyof thesedrugs are eliminated
rapidly and that plasma concentrations below the
bacterial MIC are observed throughout half of
the dosing interval. For bacteria with an MIC near
the breakpoint, it is possible that the antibiotic
concentration could be below the MIC for almost
the entire dosing interval, leading to treatment
failure [7]. It is therefore of particular interest to
study the relationship between the PK ⁄PD param-
eters and the efficacy of b-lactam antibiotics. The
aim of the present work was to evaluate a PK ⁄PD
integration of the ex-vivo PD and in-vivo PK data,
with a view to predicting the likely efficacy in
clinical use of recommended dose schedules.
MATERIALS AND METHODS
The study, which was conducted over the course of 1 year and
approved by the Ethics Committee, included 87 consecutive
patients from whom sensitive bacteria were isolated and who
were treated by the Infectious Diseases Area, University
Hospital of Navarra, with either piperacillin (with or without
tazobactam), ceftriaxone or cefepime. Antibiotic selection was
on the basis of the microorganism and its antibiogram.
Drugs were administered through a venous catheter in a
30-min infusion after dilution in 100 mL of saline 0.9% v/v.
The dose was adjusted to the renal function. Once a steady
state was reached (almost five antibiotic half-lives), venous
blood samples were taken to determine the plasma concen-
trations of the antibiotic, before and after the administration of
the drug, with two or three samples being taken in the
elimination phase. The number of blood samples, and the time
at which they were taken, depended on venous accessibility,
the clinical situation of the patient, and the patient’s consent.
The blood was collected from the arm in which drug was not
infused. Creatinine clearance was calculated according to the
Cockroft–Gault formula [8].
Clinical outcome
Infections were grouped into two categories: those in areas
easily accessedby ab-lactamantibiotic, and those in tissueswith
barriers to distribution (prostate, bone, abscesses). Clinical
response was estimated by comparing the symptoms and signs
of infection before treatment with those at the end of treatment.
The clinical outcomewas evaluated as either recovery or failure.
Recovery was defined as the partial (improvement) or total
(cure) resolution of the symptoms and signs associatedwith the
initial infection, even with persistence of radiological distur-
bances. Patients were stabilised or showed improvement with-
out the need for prolonged antibiotic treatment after leaving the
hospital. Failure was defined as persistence, worsening or
reappearance of the symptoms during treatment, or in the week
following its termination if initially considered as recovery or
improvement. In cases of chronic infection, the patients were
under surveillance for almost 6 months.
Data on other active antibiotic treatments or surgery were
included as variables that could influence the clinical outcome.
Microbiological data
Biological samples representing the infected area were taken
for routine culture. Organisms were isolated from the infec-
tious focus (urine, tracheal secretion, wound secretion or
abscesses). For endocarditis, the organism was isolated from
blood at different times. For cholecystitis, the same isolate was
obtained from bile and blood. MICs were determined with
Etests [9]. Only one infecting organism was tested for each
patient included in the study; when more than one organism
was isolated, the isolate with the higher MIC was chosen.
To facilitate statistical analysis, the isolated bacteria were
grouped as follows: (1) Gram-positive cocci; (2) Pseudomonas
aeruginosa; and (3) a group consisting of the remaining Gram-
negative bacilli. Bacteriological response was recorded when it
was possible to obtain an appropriate specimen at the end of
therapy, or when it was necessary.
Determination of antibiotic concentrations
Total concentrations of the different antibiotics were assayed
in the Pharmacokinetic Laboratory, Clinical Pharmacology
Service, University Hospital of Navarra. Levels of piperacillin,
ceftriaxone and ceftazidime were determined with the use of
fully validated high-performance liquid chromatography
methods [10–12], with a pump, an autosampler and a UV
detector set at 254 nm (Model 1050; Hewlett-Packard, Wald-
bronn, Germany).
PK data
Different PK parameters were calculated on the basis of
plasma concentration and time, using v. 5.1 of the
WINNONLIN program (Scientific Consulting Inc., Cary, NC,
USA). For the purpose of estimating the parameters, slow-
perfusion intravenous administration for 30 min, without lag-
time, and first-order elimination from the central compartment
was assumed. Three different parameters were calculated:
Cmax, defined as the concentration measured (mg ⁄L) 30 min
after the infusion; AUC0–t, defined as the area under the
concentration–time curve from 0 to a time t after the adminis-
tration of the drug (mg · h ⁄L)—the AUC was calculated
according to the log trapezoidal rule with almost four values of
concentration (13); and Cmin, defined as the concentration at
the end of the administration interval (mg ⁄L).
PK ⁄PD interaction
Different parameters were calculated separately for each
patient–treatment–organism combination on the basis of the
above data rules, according to the recommendations of
Mouton et al. [14].
Efficacy time above the MIC (T > MIC) was defined as the
time for which the plasma concentrations of the antibiotic were
above the MIC for the bacteria. This was calculated between
times t1 and t2 [6], where t1 corresponds to the time at which
the concentration reaches the MIC during the administration
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phase, and t2 corresponds to the post-infusion time at which
the plasma concentration equals the MIC in the elimination
phase (Fig. 1). The times were calculated according to the
equations
t1 ¼ MIC Cmin
Cmax  Cmin  T
t2 ¼ lnðCmax=MICÞ
k
where T is the time of maximum plasma concentration and k is
the first-order rate constant of elimination. A percentage
calculated over a 24-h period was used in the analysis.
Cmax ⁄MIC was defined as the ratio between Cmax and the
MIC.
Cmin ⁄MIC was defined as the ratio between Cmin and the
MIC.
The AUC above MIC, as determined by the trapezoidal
rule, was calculated from the plasma concentration minus the
MIC at each time interval, over a 24-h period.
The following parameters were also calculated: AUC24 ⁄ -
MIC, defined as the AUC between t1 and t2 and the MIC ratio
in a dosing interval, multiplied by the number of antibiotic
administrations received in 1 day; the free fraction of the
antibiotic, calculated from data in the literature, with a view to
calculating the efficacy-free time above the MIC (Tfree ⁄MIC);
and the minimum concentration ⁄MIC (Cminfree ⁄MIC) ratio,
with values of 80% for cefepime and piperacillin, and 5% for
ceftriaxone) [15–17]. All patients had plasma protein values in
the normal range.
Statistical analysis
An initial analysis comprised calculation of the mean, standard
deviation and median values. An analysis of the effect of each
of the independent or predictable variables on the clinical or
microbiological outcome was made with the SPSS program
v. 9.0 (SPSS Inc., Chicago, IL, USA), using two techniques of
one-by-one forward and backward stepwise introduction of
predictive variables into the model. The results were the same
with both techniques.
In each analysis, the predictive values that had an influence
on recovery were determined. The inclusion of predictive
values in the model was based on the log likelihood ratio test;
values included were those that were statistically significant if
the probability was < 0.05. All of the variables were introduced
into the analysis, including treatment duration, surgery and
concomitant antibiotics, grouped according to their effect on
the infecting microorganisms. A co-variable was considered as
a factor of confusion if, when it was withdrawn from the
model, the coefficients of the remaining variables varied by
> 15%.
An analysis was also done with a chi-square (v2) or ANOVA
test, depending on whether the variables analysed were
qualitative or quantitative, in order to evaluate the differences
in a variable depending on whether the effect measured in
each analysis was produced. Fisher’s Exact Test was used
when one or more of the v2 groups presented a series of values
of < 5. If the samples did not show a normal distribution, or if
there was no homogeneity in the variances, parametrical tests
were replaced by the corresponding non-parametrical tests
(Mann–Whitney U-test or Kruskal–Wallis test). Statistical
significance was established on the basis of p < 0.05.
RESULTS
Patients
In total, 87 patients (Table 1) were included in this
study. Infectious processes, organisms isolated
and antibiotic treatment are shown in Tables 2
and 3. The piperacillin–tazobactam combination
was used for 49 patients, piperacillin for two
patients, cefepime for 13 patients, and ceftriaxone
for the remaining 23 patients. In 62.1% of cases,
the patient also received another antibiotic.
Surgery was performed on 27.6% of the patients,
23% needed intensive care, 33% had a malignant
disease, and 9.2% suffered from diabetes mellitus.
Among cases of osteomyelitis, 62% were associ-
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Fig. 1. Illustration of the segments AUCt1 ) T and
AUCT–(t2 + T).
Table 1. Patient characteristics
Mean Range Median
Age (years) 57.9 21–88 58
Weight (kg) 71.0 50–106 71
Height (cm) 167.8 151–189 168
ClCr (mL ⁄min) 76.9 8–144 85
BMI (kg ⁄m2) 25.2 16.79–37.18 25
ClCr, creatine clearance; BMI, body mass index.
Table 2. Type of infectious disease, accessibility to antibi-
otics, and mean treatment duration by the intravenous
route
Accessibility Infection No. of patients % Mean duration (days)
Good Respiratory 37 42.52 10.6
Poor Osteomyelitis 9 10.33 10.4
Poor Prostatitis 2 2.3 20
Poor Arthritis 4 4.6 32
Poor Abscess 4 4.6 9
Good Colecystitis 4 4.6 10
Good Surgical wound 20 23 16.6
Good Fistula 6 6.9 16
Poor Endocarditis 1 1.15 35
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ated with a foreign body, which was removed
from two-thirds of these patients. Patients with
osteomyelitis required oral antibiotic therapy
(mean duration 5 months) before leaving the
hospital. Endocarditis was treated for 35 days.
An analysis of the clinical outcome was poss-
ible for all cases. In total, 65 (74.7%) patients
recovered, corresponding to 68.6% of those who
received treatment with piperacillin (± tazobac-
tam), 84.6% of those treated with cefepime, and
82.6% of those who received ceftriaxone. Treat-
ment failed in 22 patients.
Analysis according to treatment group
Patients treated with piperacillin
This group of patients included 37 males and 14
females aged 21–88 years, of whom 81.6% had
creatinine clearance values > 40 mL ⁄min. These
patients were treated with piperacillin, in most
cases in combination with tazobactam.
The organisms isolated from this group had a
mean MIC of 5.79 mg ⁄L (standard deviation
5.92 mg ⁄L). Most (40) patients received 4 g of
piperacillin with 0.5 g of tazobactam every 8 h. Of
the patients with respiratory infection, 83.3% had
an adequate clinical outcome, compared to 76.5%
of patients with infections in other locations easily
accessed by this drug, and to only 25% of patients
where there were barriers.
The mean values of the PK ⁄PD parameters
obtained from this group of patients are shown in
Table 4. The mean maximum concentration value
(156.7 mg ⁄L) in the patients who received 4 g of
piperacillin was double that obtained through the
administration of 2 g (78.5 mg ⁄L). In 14 patients,
piperacillin was not detected in the blood sample
obtained pre-dose. The plasma clearance of pip-
eracillin was directly proportional to plasma
creatinine clearance, whereas its half-life elimin-
ation was shorter when the clearance was higher.
Among the 51 patients treated with piperacil-
lin, the infectious process improved or was
resolved after antibiotic treatment in 35. Statisti-
cally significant differences were observed be-
tween both groups in terms of the MIC for the
isolated bacteria (p 0.026), the type of infection
(p < 0.001), and whether or not there was surgery
(p 0.044). When clinical outcome was inadequate,
either MIC values were higher, infection was
located in tissues with barriers, or some kind of
surgery was required. All of the PK ⁄PD variables
were different, depending on the outcome.
A gradient in the value of variables was observed
if they were analysed on the basis of the three
possible clinical outcomes, as shown in Table 5
and Fig. 2. The highest value was associated with
resolution of the infectious process.
Table 3. Organisms identified and antibiotic treatment
Bacterial
isolates
No. of
bacteria %
Piperacillin
treatment %
Cefepime
treatment %
Ceftriaxone
treatment %
Staphylococcus spp. 6 6.9 50 – 50
Enterococcus spp. 13 14.9 92.3 – 7.7
Streptococcus spp. 8 9.2 50 – 50
Enterobacteriaceae 26 29.9 50 19.2 30.8
Haemophilus
influenzae
6 6.9 – – 100
Pseudomonas
aeruginosa
24 27.6 66.7 33.3 –
Corynebacterium spp. 1 1.15 100 – –
Anaerobes 3 3.45 100 – –
Table 4. Pharmacokinetic and pharmacokinetic ⁄pharmacodynamic parameters
Parameter
Piperacillin Cefepime Ceftriaxone
Mean ± SD Median Mean ± SD Median Mean ± SD Median
Dose ⁄ administration (mg) 3843 ± 543 4000 1615.4 ± 869.7 1000 1956.5 ± 208.5 2000
Interval (h) 8 ± 2.7 8 12.2 ± 6.95 8 24 24
Total clearance (L ⁄h) 12.8 ± 6.96 11.3 5 ± 3.1 5.8 1.4 ± 0.65 1.3
AUC0–t (mg · h ⁄L) 400.5 ± 220.9 343.4 354.99 ± 205.1 260.93 1421.2 ± 674.6 1269.4
AUC0)24 (mg · h ⁄L) 1175.1 ± 567.6 1003 736.4 ± 272.8 757.4 1421.2 ± 674.6 1269.4
Peak concentration (mg ⁄L) 159.59 ± 50.21 155.59 69.86 ± 22.35 69.11 134.64 ± 51.89 120.4
Total trough concentration (mg ⁄L) 9.71 ± 14.26 4.59 16.10 ± 11.73 15.35 22.77 ± 16.29 19.78
Unbound trough concentration (mg ⁄L) 7.3 ± 10.68 3.44 12.85 ± 9.23 12.28 1.14 ± 0.8 0.99
% T > MIC 86.4 ± 18.9 98 97.3 ± 35.4 100 95.8 ± 13.74 100
% Tfree > MIC 83.2 ± 20.4 84.6 95.3 ± 8.9 100 84.2 ± 32.2 100
AUC above MIC (mg · h ⁄L) 1066.33 ± 571.3 935.6 625 ± 256.5 662.4 1330.5 ± 743.3 1173.4
AUC24 ⁄MIC (h) 1168.8 ± 3310.9 234.6 2940.5 ± 6627.3 173.6 19186.9 ± 30894 3559.9
Cmax ⁄MIC 159.9 ± 421.4 39.58 229.7 ± 508.4 15.7 1796.1 ± 2833.9 286.2
Cmin ⁄MIC 11.5 ± 53.7 0.78 75.8 ± 182.7 2.53 307.1 ± 543.4 61.7
Cmin free ⁄MIC 8.9 ± 41 0.57 60.6 ± 146 2.03 61.4 ± 109 12.3
For abbreviations, see main text.
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Patients treated with cefepime
Of the patients treated with cefepime (14.9%;
n = 13), four had severe renal dysfunction. The
mean MIC for the microorganisms identified was
4.73 ± 4.25 mg ⁄L. The clinical outcome was ade-
quate in 84.6% of these patients, and no relapses
occurred. Of the organisms isolated, 40% of
Pseudomonas aeruginosa isolates were eliminated,
as were 75% of the remaining Gram-negative
bacilli. The mean PK ⁄PD parameters calculated
for this group of patients are shown in Table 4.
The clinical outcome was satisfactory in 11
patients who received treatment with cefepime,
and no statistically significant differences
between the two groups were observed in the
non-parametric studies applied. Although there
was an apparently poorer outcome if P. aeruginosa
was isolated, this was either because the infec-
tion was located in tissues with barriers, the
patients were older, or the patients were treated
with cefepime monotherapy. Non-parametric
tests revealed statistically significant differences
in the efficacy time above the MIC of both the free
and total fractions of cefepime. No differences
were detected in other parameters, but the trend
described above for piperacillin could be detected
(Table 5).
Patients treated with ceftriaxone
Twenty-three (26.4%) patients were treated with
ceftriaxone. ThemeanMIC for the bacteria isolated
from this groupof patientswas 4.3 mg ⁄L (standard
deviation 9.11 mg ⁄L;median 0.5 mg ⁄L).One strain
of Enterobacter cloacae had an MIC of 32 mg ⁄L. The
dose and PK ⁄PD parameters for this group of
patients are shown in Table 4.
The clinical outcome was favourable for 19
patients treated with ceftriaxone, and statistically
significant differences in the MICs for the isolated
bacteria were observed between these 19 patients
and the remaining four patients (p 0.03). The
duration of treatment also differed, being shorter
in those patients with a poorer outcome (p 0.045).
The PK ⁄PD parameters also showed significant
differences, with values that gradually declined
as the clinical outcome deteriorated (Table 5). For
ceftriaxone, the magnitude of some of these
parameters was considerable even when the
outcome was inadequate. In terms of free drug
concentration, given that a high proportion of
ceftriaxone is protein-bound, this value was sim-
ilar to that observed with the other drugs studied,
and was lower in patients with an inadequate
clinical outcome.
Multivariate analysis
Table 6 shows the differences between PK ⁄PD
parameters in relation to outcome. A multivariate
analysis was done, with favourable clinical
outcome as the reference category. The probabil-
ity of an inadequate clinical outcome increased
with the presence of P. aeruginosa (p 0.039) and
Table 5. Pharmacokinetic ⁄pharmacodynamic parameters (mean values) related to treatment and clinical outcome
MIC Cmin Cmin ⁄MIC AUC above MIC AUC24 ⁄MIC Cmax ⁄MIC Cmin free Cmin free ⁄MIC
Piperacillin
Cure 3.67 13.7 7.32 1182.58 1343.96 209.85 10.3 5.49
Improvement 7.44 11.6 0.72 1463.45 232.66 28.35 8.7 0.54
Failure 8.47 2.7 0.27 718.20 156.75 30.12 2.2 0.2
p 0.021 0.008 < 0.001 0.002 < 0.001 0.009 0.008 < 0.001
Cefepime
Cure 3.14 18.2 15.2 709.35 4450.37 55.21 14.2 12.2
Improvement 5.58 18.3 2.54 608.21 2877.94 12.14 12.4 2.03
Failure 5.00 3.7 0.77 515.40 139.47 19.65 3 0.62
Ceftriaxone
Cure 1.15 22.8 451 1456.91 26524.25 2297.72 1.2 22.6
Improvement 0.87 27 199.1 1515.18 16017.37 1899.29 1.4 9.9
Failure 19.50 16.3 1.69 642.74 94.96 10.86 0.8 0.08
For abbreviations, see main text.
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Fig. 2. MIC, trough concentration and ratio in relation to
clinical outcome (the horizontal line represents the unit
value).
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the existence of barriers in the infected tissue
(p 0.005), while high values of efficacy time above
the MIC (p 0.002), AUC above MIC (p 0.04), and
higher age (p 0.039) reduced this probability
(Table 7). The surgery variable acted as a factor
of confusion, so it was retained in the model
despite the fact that its influence as a predictive
factor of clinical outcome was not significant.
DISCUSSION
The use of microbiological parameters that
provide information about the susceptibility of
an infecting pathogen is the traditional approach
to the clinical treatment of infectious disease.
These PD parameters are used to establish the
optimal antimicrobial agent for treatment. PK
data give information about the potential ability
of a drug to reach and remain at the sites of
infection, and are used to determine the dose and
the dosing interval. In clinical practice, PK para-
meters derived from the general population are
usually employed in order to establish the dose.
However, this is not a patient-specific approach;
from the perspective of optimisation of outcome
in everyday clinical practice, the best scenario
would be the employment of PK parameters
obtained directly from the individual patient.
The mean PK parameters observed in the three
groups of patients studied were similar to those
described in the general population, if renal
function was considered [18]. However, high
variability in the values of the PK parameters
was observed, with clearance values of > 50% in
many cases. Moreover, undetectable concentra-
tions at the end of the dosing interval were
observed in certain patients, especially after doses
of piperacillin.
With regard to the mean bacterial MICs for the
groups of patients studied, it was interesting to
note that this parameter was below the breakpoint
for each antibiotic in cases of recovery and failure
for patients treated with piperacillin (± tazobac-
tam) or cefepime. In the case of ceftriaxone, MICs
above the breakpoint were found exclusively for
patients with an inadequate outcome. These
results suggest that susceptibility breakpoints
were not satisfactory for a large number of
patients, as has been stated elsewhere [19]. In
the present study, the patients with an unfavour-
able outcome should have had a good response
with piperacillin or cefepime, based on the anti-
biogram. It has been reported elsewhere that,
despite the fact that the bacteria analysed are
apparently susceptible to treatment, patients with
an inadequate outcome have infecting bacteria
with higher MIC values compared to patients
who recover [3].
Based on these observations, it is necessary to
investigate other methods to improve the prog-
nosis for this group of patients. The present study
demonstrated that the integration of PK and
microbiological parameters might be of use in
the design of therapeutic regimens for b-lactams.
Thus, the time for which the concentration of
piperacillin exceeds the MIC (T > MIC or efficacy
time) is commonly considered to represent the
relevant surrogate parameter for evaluating anti-
microbial activity and therapeutic success. In the
group of patients who had a favourable outcome,
the time for which the concentration of piperacil-
lin exceeded the MIC was 97% of the dosing
interval, whereas a value of 71.5% was obtained
in patients whose outcome was inadequate.
Therefore, a value of 90% was defined for this
parameter, to differentiate between potential
recovery and failure. Traditionally, it has been
considered that T > MIC for Gram-negative
bacilli or streptococci should be equal to the
dosing interval [20,21], but the results of recent
studies have shown that it is sufficient for the
concentration to be above the MIC for 60–70% of
Table 6. Pharmacokinetic ⁄pharmacodynamic parameters
depending on clinical outcome
Recovery Failure
% time above MIC 97 ± 8.9 71.5 ± 20.5
% time above MIC (unbound) 94.5 ± 11.7 58.1 ± 27
AUC above MIC (mg · h ⁄L) 1209.7 ± 646.2 658.2 ± 282.8
AUC24 ⁄MIC (h) 8246.2 ± 20272 142.4 ± 99.7
Cmax ⁄MIC 798.1 ± 1870 26.2 ± 21.6
Cmin ⁄MIC 132.7 ± 356.8 0.5 ± 0.9
Table 7. Multivariate analysis of the influence of predictor
variables on antimicrobial treatment failure
B Standard error
p
Likelihood ratio test
Efficacy time above MIC ) 0.11 0.04 0.002
Pseudomonas
No 1 (ref.)
Yes 1.97 0.96 0.039
Age 0.07 0.04 0.040
Infection
Without barriers 1 (ref.)
With barriers 2.87 1.02 0.005
AUC above MIC ) 0.003 0.001 0.040
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the dosing interval for penicillins and cephalo-
sporins [3,22], with 50% being the value for
Gram-positive cocci [23]. The present data are
closer to the first figure, given that the outcome
was unfavourable with a mean efficacy time
above the MIC of 71.5% of the dosing interval.
In addition, a new PK ⁄PD index was identified
that is predictive of the clinical antimicrobial
effect, namely the AUC above MIC. To date, this
parameter has not been considered as a predictor
of efficacy, although Schentag et al. [6,24,25] con-
sidered this index to be the best tool for adjusting
the dosage of any antibiotic. However, its use has
detractors [26], because different plasma concen-
tration profiles can result in the same AUC values,
despite the fact that the time for which the plasma
concentration is higher than the MIC may be quite
different.
The results obtained in the present study
confirmed the need to maintain concentrations
above the MIC for a length period. Thus, the
clinical outcome in the patients depended on the
time for which the concentration of piperacillin
exceeded the MIC along the dosing interval, and
the AUC above MIC. For antibiotics that are
predominantly eliminated by the kidneys, the
plasma concentrations of drug are increased
proportionally with the dose. Similar results can
be obtained by reducing the dosing interval.
Therefore, the best way to increase the probability
of a good clinical outcome is to increase the dose
or to reduce the dosing interval. Once the maxi-
mum efficacy time above the MIC has been
achieved, the prognosis can be improved further
by increasing the AUC above MIC. This becomes
particularly important in the treatment of infec-
tious processes located at sites that b-lactams have
difficulty accessing, or for infections caused by
P. aeruginosa. This index is also a better predictor
than the efficacy time above the MIC, because
it does not have a maximum value [27].
In the present study, the clinical outcome of the
infections analysed also depended on their loca-
tion, so the probability of an inadequate outcome
was greater if they were found in tissues that are
difficult to access, such as in the case of prostate
or bone infections, or purulent collections. The
difficulty that many drugs have in accessing these
locations has been described extensively [7,28,29].
Therefore, higher AUC above MIC values and
maximum efficacy time above the MIC values in
plasma are required to reduce the probability of
treatment failure in these patients [30]. However,
in easily accessed tissues, the efficacy time and the
plasma AUC above the MIC can constitute a
accurate reflection of what occurs at the tissue
level. In tissues where the b-lactam concentration
is high (above that of plasma), the outcome of an
infectious process is more likely to be favourable,
since both the efficacy time and the AUC above
the MIC in the plasma underestimate the situation
in these tissues. This would be the case for urine
or bile [31,32].
Age was also considered to be a predictive
factor of outcome, which was better at a greater
age. Elderly patients show diminished elimin-
ation rates, including a reduction in renal clear-
ance. Therefore, drugs remain for longer periods
of time and at higher concentrations. Conse-
quently, the efficacy time above the MIC is higher
in the elderly [33].
Another determining factor of the clinical
outcome was the type of organism isolated; thus
the prognosis was clearly worse when P. aerugi-
nosa was identified as the infecting organism. The
results obtained in the present study were similar
to those reported previously [6,34]. On the other
hand, there was no difference in outcome depend-
ing on other variables, such as concomitant
antibiotics or surgery, probably because their
incidence was similar in both groups.
The analysis of the clinical outcome demon-
strated that the values of all the PK ⁄PD variables
studied were lower when treatment failed. The
data appear to support the concept that it is
necessary to maintain the plasma concentration of
a b-lactam at 4–8-fold the MIC to achieve efficacy
[35,36]. This conclusion has also been reached in
animal and in-vitro studies [37–39], and was
supported by findings in patients where an
infection produced by P. aeruginosa was detected,
with a mean Cmin ⁄MIC value of 3.56 in patients
who recovered, compared with 0.28 when the
treatment failed. The case of ceftriaxone is differ-
ent because the values were much higher, mainly
because the MIC values were much lower and the
plasma concentrations higher. Nevertheless,
the ratio calculated in terms of the fraction of
unbound drug was similar to that found for the
other two drugs, with values lower than one unit
in the patients with an inadequate outcome. The
low number of patients in some groups did not
allow statistical comparisons, although the trend
was similar.
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These observations confirm that determination
of the plasma concentration in each patient is also
useful for individualising the dosage of b-lactams,
and thus obtaining therapeutic plasma concentra-
tions. The development of PK ⁄PD parameters that
overcome the requirement to determine plasma
concentrations on a day-to-day basis to tailor the
PK system for individual patients may be more
likely to achieve the desired antimicrobial
concentration–response relationship and enable
the optimum patient–dosage regimen to be estab-
lished.
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